These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27375283)

  • 1. Long-term lamivudine therapy in chronic hepatitis B.
    Lingala S; Lau DT; Koh C; Auh S; Ghany MG; Hoofnagle JH
    Aliment Pharmacol Ther; 2016 Aug; 44(4):380-9. PubMed ID: 27375283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
    Kim JM; Choe BH; Chu MA; Cho SM
    Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
    Chen CH; Lu SN; Hung CH; Wang JH; Hu TH; Changchien CS; Lee CM
    J Hepatol; 2014 Sep; 61(3):515-22. PubMed ID: 24798617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment].
    Chen JJ; Wang ZH; Ma SW; Chen YP; Peng J; Guo YB; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):416-20. PubMed ID: 18578990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A retrospective study on HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B aged 1-7 years].
    Zhu SS; Dong Y; Xu ZQ; Wang LM; Chen DW; Gan Y; Wang FC; Yan JG; Cao LL; Wang P; Zhang HF
    Zhonghua Gan Zang Bing Za Zhi; 2016 Oct; 24(10):738-743. PubMed ID: 27938558
    [No Abstract]   [Full Text] [Related]  

  • 9. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA; Bacon BR; Di Bisceglie AM
    Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response.
    Gara N; Tana MM; Kattapuram M; Auh S; Sullivan L; Fryzek N; Walter M; Umarova R; Zhao X; Cloherty G; Doo E; Heller T; Liang TJ; Ghany MG
    Hepatol Commun; 2021 Nov; 5(11):1888-1900. PubMed ID: 34558806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up.
    Karakaya F; Özer S; Kalkan Ç; Tüzün EA; Çalışkan A; Keskin O; Kabaçam G; Karatayli S; Karatayli E; Bozdayi AM; Idilman R; Yurdaydin C
    Antivir Ther; 2017; 22(7):559-570. PubMed ID: 28240596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.
    Lenci I; Tisone G; Di Paolo D; Marcuccilli F; Tariciotti L; Ciotti M; Svicher V; Perno CF; Angelico M
    J Hepatol; 2011 Sep; 55(3):587-593. PubMed ID: 21251938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum HBsAg level and its clinical significance in lamivudine treatment for patients with HBeAg-negative acute-on-chronic liver failure.
    Lai J; Sun HX; Jie YS; Zhang K; Ke WM
    Int J Infect Dis; 2014 May; 22():78-82. PubMed ID: 24518440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years.
    Fasano M; Lampertico P; Marzano A; Di Marco V; Niro GA; Brancaccio G; Marengo A; Scotto G; Brunetto MR; Gaeta GB; Rizzetto M; Angarano G; Santantonio T
    J Hepatol; 2012 Jun; 56(6):1254-8. PubMed ID: 22343167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection.
    Yuen MF; Wong DK; Yuan HJ; Sum SM; Lai CL
    J Clin Microbiol; 2004 Oct; 42(10):4882-4. PubMed ID: 15472371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.